Arrowhead Pharmaceuticals vs Krystal Biotech
Add, change or remove companies; up to four.
KIRAβs take AI analyst
I put Arrowhead Pharmaceuticals and Krystal Biotech side by side, using each oneβs latest annual report. Here is what stands out:
- Arrowhead Pharmaceuticals is the larger business, with $829M of revenue in fiscal 2025 against $389M for Krystal Biotech, about 2.1 times as much.
- Arrowhead Pharmaceuticals grew revenue faster (23,258.2%, against 33.9%).
- Krystal Biotech kept more of each dollar of sales as operating profit (41.5% operating margin, against 11.9%).
- Krystal Biotech turned more of its sales into free cash flow (48.6% FCF margin, against 18.9%).
Who comes out ahead
Of the 8 measures where higher (or lower) is clearly better, how many each company leads.
Arrowhead Pharmaceuticals
ARWR
2/8
Revenue growthNet debt / EBITDA
Krystal Biotech
KRYS
5/8
Operating marginNet marginFCF marginReturn on equityShare count change
Side by side
Best in the row
| Latest fiscal year | ARWR FY25 | KRYS FY25 |
|---|---|---|
| Size | ||
| Market cap | $8.3B | $9.6B |
| Revenue | $829M | $389M |
| Free cash flow | $157M | $189M |
| Net income | β$1.6M | $205M |
| Growth | ||
| Revenue growth | 23,258.2% | 33.9% |
| 5-year growth | 56.6% | β |
| Share count change | 11.7% | 0.7% |
| Profitability | ||
| Gross margin | β | β |
| Operating margin | 11.9% | 41.5% |
| Net margin | β0.2% | 52.6% |
| FCF margin | 18.9% | 48.6% |
| Return on capital | β | 43.6% |
| Return on equity | β0.5% | 18.9% |
| Balance sheet | ||
| Net debt | β$665M | β$828M |
| Net debt / EBITDA | β5.5x | β5.0x |
| Dividends and buybacks | $0.0M | $0.0M |
| Valuation & quality | ||
| P/E | β | 39.0x |
| Piotroski F-score | 5 | 5 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.